Grant: CIHR Fellowship

Atrial fibrillation (AF) is the most common arrhythmia requiring medical care, with tremendous disease burden given its influence on quality of life, morbidity, and mortality. The treatment of AF requires multiple drugs use and some of these agents have serious adverse effects in the long term. It has been previously suggested that female sex is a risk factor for the development of these adverse drug reactions; however to date, the incidence of these events in women compare to these in men in the setting of AF is unknown. Thus, our main objective is to determine whether differential beneficial or adverse effects exist with drug therapy between men and women with AF.